<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994107</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-DMS-BC-17</org_study_id>
    <nct_id>NCT03994107</nct_id>
  </id_info>
  <brief_title>Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer</brief_title>
  <official_title>A Single-center, Prospective, Single Arm Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin（PLD）Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of pegylated liposomal
      doxorubicin（PLD）plus Albumin-Bound Paclitaxel and trastuzumab as neoadjuvant therapy in HER-2
      positive breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, prospective, single arm phase II study. Eligible patients will
      receive neoadjuvant therapy with pegylated liposome doxorubicin (PLD)/albumin-bound
      paclitaxel/trastuzumab regimentation.

      This study consists of two phases, the first phase aims to determine the maximum tolerated
      dose (MTD) of PLD, and the second phase will explore the efficacy and safety of the regimen.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response(pCR) rate</measure>
    <time_frame>5 months</time_frame>
    <description>Percentage of patients who do not exhibit residual invasive breast cancer in breast and lymph nodes at time of surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Breast conserving surgery</measure>
    <time_frame>5 months</time_frame>
    <description>Percentage of patients undergoing breast-conserving surgery after neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgery</measure>
    <time_frame>5 months</time_frame>
    <description>Percentage of patients undergoing mastectomy and breast-conserving surgery after neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>5 months</time_frame>
    <description>Incidence and Severity of adverse events ,according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>PLD/albumin-bound paclitaxel/Trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First phase
PLD: Level 1：30mg/m2； Level 2：35mg/m2； Level 3：40mg/m2； IV, d1, q21d×6.
albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
Trastuzumab：8mg/kg IV for the first infusion , Subsequent infusions 6mg/kg. d1, q21d×6.
Second phase
PLD: maximum tolerated dose (MTD). IV, d1, q21d×6.
albumin-bound paclitaxel: 220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
Trastuzumab：8mg/kg IV for the first infusion ,Subsequent infusions 6mg/kg. d1, q21d×6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <description>First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.
Second phase
PLD：MTD. IV, d1, q21d×6.</description>
    <arm_group_label>PLD/albumin-bound paclitaxel/Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin-bound paclitaxel</intervention_name>
    <description>220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.</description>
    <arm_group_label>PLD/albumin-bound paclitaxel/Trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.</description>
    <arm_group_label>PLD/albumin-bound paclitaxel/Trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and voluntarily receive the research procedures according to
             protocol,willingness to sign the written informed consent document;

          2. Female patients aged from 18 to 70 years old;

          3. Histologically confirmed as invasive breast cancer. occult breast cancer, inflammatory
             breast cancer and eczematoid carcinoma are ineligible;

          4. Clinical stageⅡ-Ⅲ;

          5. HER-2 Positive（defined by: IHC 3+ or ISH positive）;

          6. Without previous treatment for this breast cancer;

          7. Patients must have at least one measurable disease according to RECIST 1.1;

          8. ECOG (Eastern Cooperative Oncology Group) performance score of 0-1 points;

          9. LVEF≥55%;

         10. Normal ECG;

         11. Bone marrow function:absolute neutrophil count
             (ANC)≥2.0×109/L，platelets≥100×109/L，hemoglobin ≥90g/L。

         12. Hepatic function：alanine aminotransferase(ALT) and aspartate aminotransferase(AST)
             ≤1.5×ULN，serum total bilirubin≤ ULN;

         13. Renal function：serum creatinine≤1.5×ULN； Coagulation function：the international
             standardized ratio (INR) ≤1.5×ULN, prothrombin time (PT) or the activated partial
             thrombin time (APTT) ≤1.5×ULN.

        Exclusion Criteria:

          1. New York Heart Association (NYHA) class ≥Ⅱ heart failure.

          2. Known or suspected hypersusceptibility to any agents used in the treatment protocol.

          3. Need to Concurrent treatment with any other anti-cancer therapy considered by the
             investigator.

          4. participating in other clinical trials within 4 weeks before this study.

          5. Serious heart disease, including but not limited to:

        1) Significant ventricular arrhythmia or high degree atrioventricular block (Mobitz II or
        third degree atrioventricular block); 2) unstable angina; 3) clinically significant heart
        valve disease; 4) Electrocardiogram shows transmural myocardial infarction; 5) Uncontrolled
        hypertension. 6. Uncontrolled diabetes. 7. Severe or uncontrolled infection. 8. Hepatitis b
        surface antigen positive, or hepatitis c virus antibody positive, or human immunodeficiency
        virus (HIV) antibody positive.

        9. Active malignancy, other than adequately treated carcinoma in situ of the cervix or
        basal cell carcinoma of the skin，within the past 5 years.

        9）Women who are pregnant , breastfeeding ,or refuse to use adequate contraception prior to
        study entry and for the duration of study participation.

        10）Other conditions considered to be inappropriate to be enrolled by the investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital Chinese Academy of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Ma, MD</last_name>
    <phone>+8613910217780</phone>
    <email>13910217780@139.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fei Ma</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Ma, MD</last_name>
      <phone>+86-10-87787652</phone>
      <email>mafei@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 19, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>Fei Ma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

